简介:摘要:目的:分析研究PDCA循环管理在康复科护理不良事件管理中的应用效果。方法:随机选取2021年9月至2021年12月来我院进行治疗的康复科患者200例,随机分为对照组和实验组,每组100例。对于对照组患者采用常规的管理方法,对于实验组患者采用PDCA循环管理的方法,在实验结束后,对两组患者护理满意度情况及患者不良事件发生率进行对比分析,得出相应的研究结果。结果:在本次实验中,实验组患者护理非常满意度和护理总满意度明显优于对照组,实验组患者不良事件发生率明显低于对照组。结论:PDCA循环管理在康复科护理不良事件管理中的应用,可以实现患者不良事件发生率的有效控制,提高患者的护理满意度和护理总满意度,具有较为良好的临床应用效果,可以在临床上进行相应的推广和应用。
简介:摘要:分析与研究小剂量红霉素治疗小儿功能性消化不良的效果及复发率。方法:本次选择了我院在2018年8月至2019年8月收入与治疗的70例患儿作为研究对象,把这些患儿随机与平均分配了两组,即对照组与观察组,每组各有35例患儿,对两组患儿实施了两种治疗方式,观察组:应用小剂量红霉素治疗患儿;对照组:应用大剂量红霉素治疗患儿。通过观察两组患儿临床症状消失时间、患儿复发情况,得出治疗结论。结果:①观察组患儿的早饱、烧灼感、嗳气、恶心呕吐、上腹痛临床症状消失时间分别为2.41±0.14、3.52±0.13、2.41±0.16、2.42±0.11、3.45±0.12;对照组患儿的早饱、烧灼感、嗳气、恶心呕吐、上腹痛临床症状消失时间分别为3.39±0.12、4.58±0.12、3.37±0.23、3.36±0.01、4.51±0.21。(P
简介: 【摘 要】目的:探究他克莫司与环磷酰胺治疗狼疮性肾炎的的效果和用药不良反应率。方法:纳入观察对象 40例(均确诊为狼疮性肾炎)进行实验研究,研究时间从 2015年 3月直至 2019年 5月。采用随机分组法,将观察对象分为甲乙两组,甲组 20例患儿使用他克莫司治疗,乙组 20例患儿采取环磷酰胺治疗。观察对比两组患儿治疗效果、不良反应发生情况。结果:甲组中 1例患儿疗效不明显,另外 19例均有改善,总有效率 95%;乙组中 5例疗效不明显, 1例病情恶化,另外 14例病情改善,总有效率 70%,两组间进行比较后得到 P<0.05。治疗后随访观察到,甲组患儿 1例出现尿痛的不良反应,乙组中有 6例,两组不良反应发生率的差异显著( P<0.05)。结论:狼疮性肾炎患儿在治疗过程中可应用他克莫司与环磷酰胺进行治疗,对比发现,他克莫司可以明显提升治疗的有效率,并且控制了患儿不良反应的出现,治疗安全性得到保障,临床应用效果理想,值得推广。 【关键词】他克莫司 ;环磷酰胺 ;狼疮性肾炎 ;效果 ;不良反应率 [Abstract] Objective: To explore the effect and adverse reaction rate of tacrolimus and cyclophosphamide in the treatment of lupus nephritis. Methods: 40 patients (all diagnosed as lupus nephritis) were included in the experimental study. The study period was from March 2015 to may 2019. The observation objects were randomly divided into two groups, group A (20 cases) was treated with tacrolimus, and group B (20 cases) was treated with cyclophosphamide. The treatment effect and adverse reactions of the two groups were observed and compared. Results: in group A, the curative effect of 1 case was not obvious, the other 19 cases were improved, the total effective rate was 95%; in group B, the curative effect was not obvious in 5 cases, 1 case was deteriorated, the other 14 cases were improved, the total effective rate was 70%, the comparison between the two groups showed that P < 0.05. After treatment, 1 case of adverse reactions occurred in group A and 6 cases in group B. There was a significant difference in the incidence of adverse reactions between the two groups (P < 0.05). Conclusion: tacrolimus and cyclophosphamide can be used in the treatment of children with lupus nephritis. Compared with cyclophosphamide, tacrolimus can significantly improve the efficiency of treatment, and control the occurrence of adverse reactions in children. The safety of treatment is guaranteed and the clinical application effect is ideal, which is worthy of promotion.